ORPHA:158019
Indeterminate cell histiocytosis
Also known as: Indeterminate dendritic cell neoplasm · Indeterminate dendritic cell tumor
Publications
576
87.2th percentile
Trials
0
Interventional, condition-specific
Researchers
1,235
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare neoplastic disease characterized by multiple, and on occasion single, asymptomatic, smooth, red-brown papulonodules located on the face, neck, trunk and/or extremities which present a nonepidermotrophic histiocytic infiltrate with immunohistochemical features of both Langerhans and non-Langerhans cells (i.e. immunopositive for S100 protein and CD1a in the absence of Birbeck granules and langerin expression).
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0015538
- UMLS:C2825741
- NCIT:C81767
Additional Mondo synonyms (4)
indeterminate Dendritic cell tumor · indeterminate Dendritic cell tumour · indeterminate cell histiocytosis · indeterminate dendritic cell tumor
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
576 matched papers (364 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPartial
None under the specific name; 68 for broader category histiocytosis
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
576
576 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
576 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
364 in the last 10 years · high confidence · 87.2th percentile (publications denominator)
Phrase hits: 576 · MeSH hits: 0
Who's working on it?
1,235
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Li J5 papers · 2025
Department of Oncology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
Papers in Europe PMC - 02Wang L4 papers · 2026
Department of Hematology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Papers in Europe PMC - 03Zhang Y4 papers · 2026
Institute of Hematology, Union Hospital, Tongji Medicine College, Huazhong University of Science and Technology, Wuhan, China.
Papers in Europe PMC - 04Abeykoon JP3 papers · 2025
Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Papers in Europe PMC - 05Cai H3 papers · 2022
Department of Hematology, Peking Union Medical Hospital, Dongcheng District, Chinese Academy of Medical Sciences and Peking Union Medical College, 1 Shuai Fu Yuan Hu Tong, Beijing, 100730, People's Republic of China.
Papers in Europe PMC - 06Cao X3 papers · 2026
Institute of Hematology, Union Hospital, Tongji Medicine College, Huazhong University of Science and Technology, Wuhan, China.
Papers in Europe PMC - 07Chen Y3 papers · 2026
College of Traditional Chinese Medicine, Hubei University of Chinese Medicine, Wuhan, China.
Papers in Europe PMC - 08Emile JF3 papers · 2026
Paris-Saclay University, Versailles SQY University, EA4340-BECCOH, Assistance Publique-Hôpitaux de Paris (AP-HP), Ambroise-Paré Hospital, Smart Imaging, Service de Pathologie, 92100 Boulogne, France.
Papers in Europe PMC - 09Li Y3 papers · 2023
*Department of Dermatology, Second Xiangya Hospital, Central South University, Changsha, China; and†Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA.
Papers in Europe PMC - 10Tzankov A3 papers · 2026
Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 68 trials are registered for histiocytosis, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
68 interventional trials matched histiocytosis, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: histiocytosis
68
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT05997602·RECRUITING·To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCH
Conditions: Langerhans Cell Histiocytosis · LCH·Matched via name phrase
- NCT04079179·RECRUITING·Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
Conditions: Langerhan's Cell Histiocytosis · Juvenile Xanthogranuloma · Erdheim-Chester Disease · Rosai Dorfman Disease·Matched via name phrase
- NCT06153173·RECRUITING·Mirdametinib in Histiocytic Disorders
Conditions: Langerhans Cell Histiocytosis (LCH) · Juvenile Xanthogranuloma (JXG) · Rosai-Dorfman Disease (RDD) · Histiocytic Disorders·Matched via name phrase
- NCT07440290·NOT YET RECRUITING·DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
Conditions: Haematological Malignancy · Malignant Neoplasm · Lymphoproliferative Disorders · Neoplasms by Histologic Type·Matched via name phrase
- NCT04943198·RECRUITING·Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis
Conditions: Histiocytosis·Matched via name phrase
- NCT07431060·RECRUITING·Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell Histiocytosis
Conditions: Langerhans Cell Histiocytosis (LCH)·Matched via name phrase
- NCT06582745·RECRUITING·Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib
Conditions: Langerhans Cell Histiocytosis·Matched via name phrase
- NCT06902792·ENROLLING BY INVITATION·Adebrelimab Combined With Trametinib in the Treatment of Refractory Recurrent Langerhans Cell Histiocytosis in Children and Adolescents
Conditions: Histiocytosis, Langerhans-Cell·Matched via name phrase
- NCT06078969·RECRUITING·Oral Prednisone in Treating LCH of Bone in Childhood and Adolescence
Conditions: Langerhans Cell Histiocytosis of Bone·Matched via name phrase
- NCT04943211·RECRUITING·Determination of Molecular Status, the Efficacy and Safety of Fluorodeoxyglucose in PET-CT Imaging
Conditions: Histiocytosis·Matched via name phrase
- NCT04943224·RECRUITING·Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients
Conditions: Histiocytosis·Matched via name phrase
- NCT06712810·RECRUITING·Q702 for the Treatment of Patients With Hematologic Malignancies
Conditions: Hematopoietic and Lymphatic System Neoplasm · Histiocytic Sarcoma · Malignant Histiocytosis · Peripheral T-Cell Lymphoma, Not Otherwise Specified·Matched via name phrase
- NCT05786924·RECRUITING·Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Conditions: Non-small Cell Lung Cancer · Histiocytic Neoplasm · Histiocytosis · BRAF Gene Mutation·Matched via name phrase
- NCT02670707·RECRUITING·Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
Conditions: Langerhans Cell Histiocytosis·Matched via name phrase
- NCT07022834·RECRUITING·Real-world Study of Darafenib or Trametinib and Clofarabine for High-risk/Recurrent/Refractory Langerhans Cell Histiocytosis in Children
Conditions: Langerhans Cell Histiocytosis (LCH)·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Indeterminate cell histiocytosis" OR "Indeterminate dendritic cell neoplasm" OR "Indeterminate dendritic cell tumor" OR "indeterminate Dendritic cell tumour"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Indeterminate cell histiocytosis" OR "Indeterminate dendritic cell neoplasm" OR "Indeterminate dendritic cell tumor" OR "indeterminate Dendritic cell tumour"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"histiocytosis"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T08:05:35.334Z
